Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Marmara University
City of Hope Medical Center
Children's Oncology Group
Faron Pharmaceuticals Ltd
Pfizer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Blood Cancer United
M.D. Anderson Cancer Center
Brigham and Women's Hospital
Jonsson Comprehensive Cancer Center
M.D. Anderson Cancer Center
ImCheck Therapeutics
Byondis B.V.
M.D. Anderson Cancer Center
Weill Medical College of Cornell University
City of Hope Medical Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Mayo Clinic
BeOne Medicines
Cedars-Sinai Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Rochester
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Massachusetts General Hospital
M.D. Anderson Cancer Center
City of Hope Medical Center
University of Washington
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center